SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted Patent Number 11,357,463: titled, “Target Site Selection, Entry and Update With Automatic Remote Image Annotation”, with a patent term that will expire in late 2034.
Taiwan To Elon Musk: ‘Our Freedom And Democracy Are Not For Sale’
Taiwan’s de-facto ambassador came down heavily on Tesla Inc (NASDAQ: TSLA) CEO Elon Musk’s take on solving the cross-straits tensions with China by
